We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Spanish biotech SpliceBio has raised $135 million in financing that will help it move a gene-editing therapy for an inherited retinal disease (IRD) through clinical testing. SpliceBio's lead in-house ...